Home

ANNE VANLENT

CIK 1229243 · Exec VP & CFO · last filed 2026-06-04

ANNE VANLENT is an Exec VP & CFO who has filed 59 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for TRVI, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$130.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $592.8K across reported positions. 3 SEC filings were submitted jointly with QLT INC/BC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$592.8K

Companies

12

Total Filings

59

Lifetime Open-Market Net

-$130.4K

Filer Profile

Reported Address
C/O TREVI THERAPEUTICS, INC.
NEW HAVEN, CT 06510
Related Filers
QLT INC/BC — 3 joint filings, latest 2016-12-27
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TRVI Director 20,983 $15.20 $318.9K $50.0K 10 2026-06-04
APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Director — $0.39 — $0 9 2022-12-01
Vaxart, Inc. (VXRT) Delisted Director — $0.32 — $0 1 2019-06-14
AVIR Director — $5.50 — $0 2 2017-05-22
NOVELION THERAPEUTICS INC. (NVLN) Delisted Director — — — $0 1 2016-12-27
Aegerion Pharmaceuticals, Inc. (AEGR) Delisted Director 0 — — $0 3 2016-11-30
Vaxart, Inc. (BOTA) Delisted Director 35,000 — — $76.9K 4 2015-08-13
ONTX Director — $14.69 — $0 3 2015-06-17
Ocera Therapeutics, Inc. (TZYM) Delisted Director — — — $0 2 2012-08-09
IART Director 16,956 $16.15 $273.8K -$250.3K 8 2012-05-21
PENWEST PHARMACEUTICALS CO (PPCO) Delisted Director 0 — — -$7.0K 8 2010-09-22
BARRIER THERAPEUTICS INC (BTRX) Delisted Exec VP & CFO 148,852 — — $0 2 2008-03-17

Recent Filings

59 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-04 TRVI Grant (A) — $0 EDGAR
2025-06-13 TRVI Grant (A) — $0 EDGAR
2024-06-14 TRVI Grant (A) — $0 EDGAR
2023-06-30 TRVI Grant (A) — $0 EDGAR
2022-12-01 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Disp (D) — $0 EDGAR
2022-07-01 TRVI Grant (A) — $0 EDGAR
2022-06-23 TRVI Grant (A) — $0 EDGAR
2021-12-02 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Grant (A) — $0 EDGAR
2021-06-17 TRVI Grant (A) — $0 EDGAR
2020-12-18 APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 59
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.